Clinical Trials Browser

Completed × Hsp90 inhibitor KU757 × Dermatologic × Clear all

NCT01657591 2023-01-19

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Completed

Melanoma, Skin Neoplasms